Outlook Therapeutics (OTLK) Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OTLK Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Outlook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.26 |
| 52 Week High | US$6.98 |
| 52 Week Low | US$0.79 |
| Beta | 0.57 |
| 1 Month Change | 18.87% |
| 3 Month Change | -37.31% |
| 1 Year Change | -79.17% |
| 3 Year Change | -94.11% |
| 5 Year Change | -92.32% |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| OTLK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.4% | 2.8% | -0.2% |
| 1Y | -79.2% | 4.0% | 20.3% |
Return vs Industry: OTLK underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: OTLK underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| OTLK volatility | |
|---|---|
| OTLK Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OTLK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OTLK's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 23 | Bob Jahr | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
Outlook Therapeutics, Inc. Fundamentals Summary
| OTLK fundamental statistics | |
|---|---|
| Market cap | US$55.97m |
| Earnings (TTM) | -US$43.44m |
| Revenue (TTM) | US$1.51m |
Is OTLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTLK income statement (TTM) | |
|---|---|
| Revenue | US$1.51m |
| Cost of Revenue | US$41.88m |
| Gross Profit | -US$40.37m |
| Other Expenses | US$3.07m |
| Earnings | -US$43.44m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -2,681.93% |
| Net Profit Margin | -2,885.82% |
| Debt/Equity Ratio | -92.6% |
How did OTLK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 03:52 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Outlook Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |